A biotech startup called Omega Therapeutics debuts this morning touting a new approach to developing medicines based on epigenetics, a field of research that has tantalized drug makers for years but produced mixed results. Can the fledgling company surpass previous efforts... Read more »
Boston, San Francisco, and a few other metro areas might dominate the US life sciences, but some weeks, all bio-related eyes are on the nation’s capital. Health concerns about vaping continue to mount, and the feds could get involved. Meanwhile, try... Read more »
With the 2020 election just over a year away, House Speaker Nancy Pelosi (D-CA) has unveiled the Democratic Party’s answer to public discontent over high prescription drug prices.
A preview of the plan was leaked last week. Today’s announcement doesn’t... Read more »
[Corrected 9/17/2019, 8:58 a.m, and 9/18/19, 4:53 p.m. See below.] Fieldwire, whose mobile app helps builders and construction crews coordinate their work, announced today it has lined up a total of $33.5 million across two newly disclosed fundraising... Read more »
Add another once-promising Alzheimer’s disease drug to the scrap heap.
Eisai and Biogen (NASDAQ: BIIB) are halting a Phase 3 test after an independent safety review concluded the risks of experimental Alzheimer’s drug elenbecestat outweigh the benefits. The companies did... Read more »
[Updated 9/13/19, 11:40 am ET. See below.] Cloudflare has had its share of controversy, and is in a market with a wide range of more established competitors, from Amazon Web Services and Google Cloud to Cisco Systems and Palo... Read more »
For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy. If a medical meeting in Barcelona this week was any indication, more help could be on the... Read more »
Wall Street welcomed three life science companies to the public markets this week. 10x Genomics led the way Wednesday, followed by SpringWorks Therapeutics and Satsuma Pharmaceuticals on Thursday. Combined, the three companies raised more than $595 million from their IPOs.
According... Read more »
The consumerization of healthcare is accelerating. Within five years, a “significant percentage” of healthcare services will be run through mobile apps and other digital tools, predicts John Halamka, a Boston-based doctor and prominent digital health expert.
Halamka shared his prognostication in... Read more »
Phil Sharp is one of the godfathers of biotech. He’s an MIT biologist, Nobel laureate and, as a Biogen (NASDAQ: BIIB) co-founder, one of the people responsible for turning Kendall Square into the biopharma epicenter it is today.
Next month,... Read more »
The first details of the long-awaited House Democrat plan to lower drug prices leaked out Monday night, with elements that have long been anathema to the biopharma industry and its supporters in Washington.
While the world digested the details Tuesday, however,... Read more »
This year’s Lasker Awards, the US’s most prestigious biomedical honor, are going to five scientists whose work led to a critical breast cancer treatment and significant basic research advances that have helped pave the way for immunotherapy.
H. Michael Shepard, Dennis... Read more »
Gene-editing technology offers the potential to treat inherited disorders with selective edits and corrections to an afflicted individual’s genetic code. But with such molecular tinkering comes with the risk of unintended changes to the genome.
Biotech startup Trucode Gene Repair is... Read more »